Pelthos Therapeutics Inc. Stock-Based Compensation
Pelthos Therapeutics Inc. (PTHS) reported Stock-Based Compensation of $4.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Pelthos Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.76M, a 568.28% increase year-over-year.
- Pelthos Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.91M, a 292.59% increase year-over-year.
- Pelthos Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.80M, a 239.43% increase year-over-year.
- Pelthos Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.76M, a 433.94% increase year-over-year.
- Pelthos Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $5.46M, a 203.56% increase from fiscal 2024.
- Pelthos Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.80M, a 3.79% increase from fiscal 2023.
- Pelthos Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.73M, a 1473.58% increase from fiscal 2022.
- Pelthos Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $110.15K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.76M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $4.67M 10-Q · filed 2026-08-13 | $6.47M derived: sum of 3 quarters · filed 2026-08-13 | $9.23M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.91M 10-Q/A · filed 2026-08-13 | $3.71M derived: sum of 2 quarters · filed 2026-08-13 | $6.47M derived: sum of 3 quarters · filed 2026-08-13 | $6.88M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.56M derived: sum of 2 quarters · filed 2026-03-19 | $4.97M derived: sum of 3 quarters · filed 2026-08-13 | $5.46M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $2.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.18M derived: sum of 2 quarters · filed 2026-08-13 | $3.66M 10-Q · filed 2025-11-13 | $4.19M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $413.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $899.00K 10-Q · filed 2026-08-13 | $899.32K 10-Q · filed 2025-08-13 | $1.43M derived: sum of 3 quarters · filed 2026-08-13 | $1.95M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $486.00K 10-Q/A · filed 2026-08-13 | $485.83K 10-Q · filed 2025-05-13 | $1.02M derived: sum of 2 quarters · filed 2026-08-13 | $1.53M derived: sum of 3 quarters · filed 2026-08-13 | $1.99M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2024-12-31 | $530.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.05M derived: sum of 2 quarters · filed 2026-03-19 | $1.51M derived: sum of 3 quarters · filed 2026-03-19 | $1.80M 10-K · filed 2026-03-19 | $1.80M 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $517.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $976.45K derived: sum of 2 quarters · filed 2025-11-13 | $1.27M 10-Q · filed 2025-11-13 | $1.27M 10-Q · filed 2024-11-13 | $2.06M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $458.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $751.53K 10-Q · filed 2025-08-13 | $1.54M derived: sum of 3 quarters · filed 2025-08-13 | $1.89M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $292.55K 10-Q · filed 2025-05-13 | $1.08M derived: sum of 2 quarters · filed 2025-05-13 | $1.43M derived: sum of 3 quarters · filed 2025-05-13 | $1.75M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $791.24K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.13M derived: sum of 2 quarters · filed 2025-03-27 | $1.46M derived: sum of 3 quarters · filed 2025-03-27 | $1.73M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $342.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $669.77K derived: sum of 2 quarters · filed 2024-11-13 | $941.99K 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | $327.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $599.56K 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | $272.22K 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | $110.15K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |